MedDataX Logo

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

NCT ID: NCT02365636

Last Updated: 2021-11-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-26

Study Completion Date

2017-05-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to evaluate the safety and efficacy of 4% and 8% w/w TV 45070 ointment compared with placebo ointment applied topically and twice daily to the area of PHN pain for 4 weeks in patients with PHN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postherpetic Neuralgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TV-45070 4%

TV-45070 ointment in a 4% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.

Group Type EXPERIMENTAL

TV-45070

Intervention Type DRUG

TV-45070 is an ointment applied topically twice daily to area of pain.

TV-45070 8%

TV-45070 ointment in a 8% strength applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.

Group Type EXPERIMENTAL

TV-45070

Intervention Type DRUG

TV-45070 is an ointment applied topically twice daily to area of pain.

Placebo

Placebo ointment applied topically twice daily to the area of postherpetic neuralgia (PHN) pain during the treatment period from days 1 through 28.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TV-45070

TV-45070 is an ointment applied topically twice daily to area of pain.

Intervention Type DRUG

Placebo

The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

funapide XEN402

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient has chronic Postherpetic Neuralgia (PHN), defined as pain present for more than 6 months and less than 10 years after onset of herpes zoster skin rash affecting a single dermatome. Patients with more than 1 involved dermatome may also be included, provided the affected dermatomes are contiguous.
* Patient is ≥18 years of age, with a body mass index (BMI) between 18 and 34 kg/m2, inclusive, at the screening visit.
* If the patient is a woman and is fertile, the patient is not pregnant and has negative pregnancy tests at both the screening and randomization visits, and agrees to use an acceptable method of contraception for the duration of the study, including follow-up.
* If the patient is a man and is capable of producing offspring, the patient must agree to use an acceptable method of contraception, unless the partner cannot become pregnant for the duration of the study, including follow-up.
* Patient must sign the written Informed Consent Form (ICF) for the study and be willing to comply with all study procedures and restrictions.
* Patient must be judged by the investigator to be medically healthy (except for PHN) and able to participate in the study

* Other criteria apply, please contact the investigator for more information

Exclusion Criteria

* Patient has any other severe pain that might confound assessment or self-evaluation of pain due to PHN.
* Patient has PHN affecting the face (trigeminal nerve distribution).
* Patient has a history, in the judgment of the investigator, of inadequate response to more than 3 adequate courses of treatment with other medications used to treat neuropathic pain (eg, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, anticonvulsants, topical lidocaine, and/or topical capsaicin).
* Patient is taking oral analgesics (either opioid or non-opioid) or is receiving topical therapy such as the 5% topical lidocaine patch for the treatment of pain and is unwilling or unable to complete a washout period during which the patient will discontinue analgesic therapy or topical pain therapy.
* Patient has been treated with topical capsaicin at any time in the past 6 months for neuropathic pain.
* Patient has a history of fibromyalgia.

* Other criteria apply, please contact the investigator for more information
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Teva Medical Expert, MD

Role: STUDY_DIRECTOR

Teva Branded Pharmaceutical Products R&D, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Teva Investigational Site 13052

Birmingham, Alabama, United States

Site Status

Teva Investigational Site 13086

Mobile, Alabama, United States

Site Status

Teva Investigational Site 13514

Phoenix, Arizona, United States

Site Status

Teva Investigational Site 13520

Phoenix, Arizona, United States

Site Status

Teva Investigational Site 13661

Little Rock, Arkansas, United States

Site Status

Teva Investigational Site 13079

Colton, California, United States

Site Status

Teva Investigational Site 13331

Pomona, California, United States

Site Status

Teva Investigational Site 13341

Sacramento, California, United States

Site Status

Teva Investigational Site 13051

Santa Monica, California, United States

Site Status

Teva Investigational Site 13055

Thousand Oaks, California, United States

Site Status

Teva Investigational Site 13100

Torrance, California, United States

Site Status

Teva Investigational Site 13657

Milford, Connecticut, United States

Site Status

Teva Investigational Site 13521

Brandon, Florida, United States

Site Status

Teva Investigational Site 13085

Brooksville, Florida, United States

Site Status

Teva Investigational Site 13057

Clearwater, Florida, United States

Site Status

Teva Investigational Site 13084

Fort Myers, Florida, United States

Site Status

Teva Investigational Site 13047

Hialeah, Florida, United States

Site Status

Teva Investigational Site 13046

Homestead, Florida, United States

Site Status

Teva Investigational Site 13098

Jacksonville, Florida, United States

Site Status

Teva Investigational Site 13045

Kissimmee, Florida, United States

Site Status

Teva Investigational Site 13064

Miami, Florida, United States

Site Status

Teva Investigational Site 13338

Miami, Florida, United States

Site Status

Teva Investigational Site 13044

Miami, Florida, United States

Site Status

Teva Investigational Site 13335

Miami, Florida, United States

Site Status

Teva Investigational Site 13522

Naples, Florida, United States

Site Status

Teva Investigational Site 13058

New Port Richey, Florida, United States

Site Status

Teva Investigational Site 13076

Oldsmar, Florida, United States

Site Status

Teva Investigational Site 13073

Orlando, Florida, United States

Site Status

Teva Investigational Site 13048

Orlando, Florida, United States

Site Status

Teva Investigational Site 13659

Pembroke Pines, Florida, United States

Site Status

Teva Investigational Site 13519

Seminole, Florida, United States

Site Status

Teva Investigational Site 13056

St. Petersburg, Florida, United States

Site Status

Teva Investigational Site 13059

Tampa, Florida, United States

Site Status

Teva Investigational Site 13329

Venice, Florida, United States

Site Status

Teva Investigational Site 13513

Virginia Gardens, Florida, United States

Site Status

Teva Investigational Site 13053

Atlanta, Georgia, United States

Site Status

Teva Investigational Site 13063

Marietta, Georgia, United States

Site Status

Teva Investigational Site 13091

Aurora, Illinois, United States

Site Status

Teva Investigational Site 13072

Bolingbrook, Illinois, United States

Site Status

Teva Investigational Site 13062

Evansville, Indiana, United States

Site Status

Teva Investigational Site 13093

Evansville, Indiana, United States

Site Status

Teva Investigational Site 13074

Monroe, Louisiana, United States

Site Status

Teva Investigational Site 13660

Shreveport, Louisiana, United States

Site Status

Teva Investigational Site 13094

Brockton, Massachusetts, United States

Site Status

Teva Investigational Site 13061

Detroit, Michigan, United States

Site Status

Teva Investigational Site 13049

Farmington Hills, Michigan, United States

Site Status

Teva Investigational Site 13099

St Louis, Missouri, United States

Site Status

Teva Investigational Site 13065

Las Vegas, Nevada, United States

Site Status

Teva Investigational Site 13066

Albuquerque, New Mexico, United States

Site Status

Teva Investigational Site 13330

Albuquerque, New Mexico, United States

Site Status

Teva Investigational Site 13658

Albany, New York, United States

Site Status

Teva Investigational Site 13334

Brooklyn, New York, United States

Site Status

Teva Investigational Site 13054

New York, New York, United States

Site Status

Teva Investigational Site 13083

North Massapequa, New York, United States

Site Status

Teva Investigational Site 13060

Calabash, North Carolina, United States

Site Status

Teva Investigational Site 13337

Raleigh, North Carolina, United States

Site Status

Teva Investigational Site 13082

Winston-Salem, North Carolina, United States

Site Status

Teva Investigational Site 13089

Columbus, Ohio, United States

Site Status

Teva Investigational Site 13075

Oklahoma City, Oklahoma, United States

Site Status

Teva Investigational Site 13328

Oklahoma City, Oklahoma, United States

Site Status

Teva Investigational Site 13516

Oklahoma City, Oklahoma, United States

Site Status

Teva Investigational Site 13078

Eugene, Oregon, United States

Site Status

Teva Investigational Site 13333

Levittown, Pennsylvania, United States

Site Status

Teva Investigational Site 13339

Philadelphia, Pennsylvania, United States

Site Status

Teva Investigational Site 13327

Pittsburgh, Pennsylvania, United States

Site Status

Teva Investigational Site 13332

Charleston, South Carolina, United States

Site Status

Teva Investigational Site 13068

Rapid City, South Dakota, United States

Site Status

Teva Investigational Site 13095

Knoxville, Tennessee, United States

Site Status

Teva Investigational Site 13096

Memphis, Tennessee, United States

Site Status

Teva Investigational Site 13070

Arlington, Texas, United States

Site Status

Teva Investigational Site 13088

Austin, Texas, United States

Site Status

Teva Investigational Site 13340

McKinney, Texas, United States

Site Status

Teva Investigational Site 13050

Plano, Texas, United States

Site Status

Teva Investigational Site 13518

Salt Lake City, Utah, United States

Site Status

Teva Investigational Site 13090

Norfolk, Virginia, United States

Site Status

Teva Investigational Site 13081

Bellevue, Washington, United States

Site Status

Teva Investigational Site 13336

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Fetell M, Sendel M, Li T, Marinelli L, Vollert J, Ruggerio E, Houk G, Dockum M, Albrecht PJ, Rice FL, Baron R. Cutaneous nerve fiber and peripheral Nav1.7 assessment in a large cohort of patients with postherpetic neuralgia. Pain. 2023 Nov 1;164(11):2435-2446. doi: 10.1097/j.pain.0000000000002950. Epub 2023 Jun 27.

Reference Type DERIVED
PMID: 37366590 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TV-45070-CNS-20013

Identifier Type: -

Identifier Source: org_study_id